NB-5-MeO-DALT

NB-5-MeO-DALT, also called 5-MeO-DALT BOC or NBoc-5-MeO-DALT, is a protected derivative of the tryptamine 5-MeO-DALT. The “NB” label can be misleading: in this compound it refers to an N-tert-butoxycarbonyl (N-Boc) group on the indole nitrogen, not an N-benzyl substituent. It appeared in online research-chemical listings in 2022, but published information about its pharmacology, metabolism and effects in humans is extremely limited.

Chemistry

NBoc-5-MeO-DALT retains the 5-methoxytryptamine framework and the N,N-diallyl substitution of 5-MeO-DALT. The indole nitrogen is protected with a tert-butoxycarbonyl group. This makes it chemically distinct from 5-MeO-DALT itself and from N-benzylated tryptamines.

The compound is sometimes listed under the shorter name NB-5-MeO-DALT. That shorthand should not be read as evidence that it belongs to the NBOMe or N-benzylphenethylamine families. Its structure is a Boc-protected tryptamine.

Relationship to 5-MeO-DALT

5-MeO-DALT is a substituted tryptamine with reported serotonergic psychedelic activity. NBoc-5-MeO-DALT is a protected derivative of that parent compound. Some secondary descriptions suggest that the protecting group may be removed under conditions involving substantial heat, but this has not been established through controlled human pharmacokinetic or pharmacodynamic studies.

A 2022 report on emerging psychoactive substances listed NBoc derivatives of 5-MeO-DALT and 5-MeO-MiPT among newly encountered products. The report documents their appearance and chemical identification, rather than providing a validated human effect profile (Yurchenko and colleagues, Recent trends in the identification of psychoactive substances, 2022).

Pharmacology and reported effects

No compound-specific receptor-binding study or controlled human study has established the pharmacology of NBoc-5-MeO-DALT. The effects of 5-MeO-DALT cannot simply be assigned to its Boc-protected derivative. In particular, there is no reliable evidence defining whether the protected compound itself produces psychedelic effects or how it is transformed in the human body.

For this reason, a detailed list of visual, cognitive or physical effects would be speculative. Reports about the parent compound 5-MeO-DALT should be kept separate from observations about NBoc-5-MeO-DALT.

Toxicity and research limitations

Detailed clinical cases, human pharmacokinetic data and toxicological studies specific to NBoc-5-MeO-DALT are lacking. Its metabolism, possible conversion to the parent tryptamine, acute toxicity and long-term effects remain unknown.

The lack of published adverse-event reports should not be interpreted as evidence of safety. The identity of products sold under abbreviated research-chemical names should also be confirmed analytically, since names alone do not guarantee the chemical composition.

Related compounds

NBoc-5-MeO-DALT is related to 5-MeO-DALT and NB-5-MeO-MiPT. Both NBoc derivatives share the protected indole nitrogen, while their side-chain substitutions differ.